The European hemp and cannabis group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) announces the integration of greensby with the acquisition of 50.2 % of the shares. This strategic move creates a unique platform that bundles all of the Group’s products and services and comprehensively covers the entire hemp and cannabis market.

greensby is a central platform that connects patients, pharmacies, telemedicine providers and consumers and enables the comparison of cannabis products. Following its integration into SYNBIOTIC, greensby is now expanding its range to include hemp products and cultivation accessories for recreational cannabis, offering up to 4,000 products. This makes greensby a comprehensive point of contact for all hemp and cannabis-related needs.

Only greensby compares in this way

greensby is one of the largest comparison portals for medicinal cannabis in Europe. Here, users can find information on all the prices of the most popular pharmacies and also find separate subpages for each strain with useful information, batch-dependent cannabinoid and terpene profiles. The sophisticated rating system also allows users to find a strain that has already helped other people with similar symptoms. The aim is to make greensby the most visited portal in the cannabis industry.

“A question that has been driving me for some time: What if a single platform could unite all the needs of the hemp and cannabis industry? With greensby, we’re making that possible,” explains Emilio Ropero, CCO SYNBIOTIC. “From cannabis patients to consumers – we are creating an interface to optimally cover the needs of all market participants.

The greensby platform is user-friendly, customer-orientated and indexes the entire market. This makes it an absolute added value in terms of marketing for everyone involved – from consumers to our partners and investors.”

Everything under one roof

For pharmacies, greensby offers a comprehensive solution that significantly simplifies entry into the medical cannabis market. In addition to a comprehensive database with information on products, terpene profiles and batches, user-friendly software with integrated inventory, payment options and interfaces to wholesalers is available. All processes, from ordering to delivery, are efficiently organised also thanks to the logistical connection to partners such as DHL and GO. In addition, training is offered for pharmacy staff to ensure that they are always up to date.

Prescribers of cannabis medicines, including telemedicine practitioners, benefit from trustworthy information on medicinal cannabis and a daily updated inventory overview of pharmacies. This enables better care for patients and significantly reduces waiting times for required medication.

Patients are at the centre of greensby. The platform simplifies the entire process, from the consultation with the doctor to the delivery of medication. Patients can compare and evaluate strains and view their availability in pharmacies. A specially developed digital assistant supports the selection of strains and, if desired, refers patients directly to prescribers of cannabis medicines.

Daniel Kruse, Managing Director of SYNBIOTIC, emphasises: “Our absolutely unique selling point is that our buy-and-build strategy unites the entire industry on one platform – and we are now also presenting this in digitalised form on greensby.de. There is nothing like this on the market yet. We are creating a transparent, optimised and accessible solution for everyone involved.”

Adam Szajcz, CEO of greensby, adds: “With greensby, we are facilitating communication and interaction across the entire industry. Among other things, we are connecting hundreds of pharmacies and creating Germany’s largest community for cannabis patients. We will be releasing a new version of our platform in December, on which we will also integrate the other business areas of the SYNBIOTIC Group.”

Shaping the future together

With the integration of greensby, SYNBIOTIC is taking a decisive step towards digitalisation and increased efficiency. The platform invites the community, partners and investors to play an active role in shaping the future of the industry. It is more than just a project – greensby is part of the future of the hemp and cannabis industry.

Publisher
SYNBIOTIC SE
Daniel Kruse
Managing Director
Münsterstrasse 336
40470 Düsseldorf
Germany

Media contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a publicly listed group of companies in the hemp and cannabis sector with a buy-and-build investment strategy focussed on the EU.
The Group covers the entire value chain from cultivation to production and retail – from the field to the shelf. The subsidiaries’ core businesses are research and development, production and the commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC is pursuing a clear pan-European strategy to further expand along the value chains of its business areas – hemp and CBD, medical cannabis and consumer cannabis – and thus cover the relevant growth markets while increasing opportunities for investors through diversification.

Ad hoc: Comment on withdrawn non-binding offer

Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO)

Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) (“Evotec”) for EUR11.00 per share in cash.

The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec.

The Management Board and Supervisory Board continue to have strong conviction in the Company’s standalone strategy, which is expected to accelerate growth, strengthen the long-term profitability of the Company and deliver significant value to shareholders.

– End of the ad hoc release –

Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com

Vita 34 continues to show increasing revenue, improved profitability and stronger cash generation in the third quarter of 2024

• Revenue up 6.3 percent to EUR 60.3 million for the first nine months of 2024
• EBITDA grows by 77.5 percent to EUR 6.4 million, also driven by positive one-time effects
• EBITDA margin returns to double-digit level at 10.6 percent
• Strong operating cash flow of EUR 7.8 million, up 61.1 percent

Leipzig, 22 November 2024 – Vita 34 AG, the leading cell bank in Europe and the third largest worldwide, accelerated its revenue growth rate and earnings in the third quarter of 2024 despite the prolonged challenging macroeconomic environment.

Revenues for the first nine months of 2024 increased by 6.3 percent year-on-year to EUR 60.3 million (9M 2023: EUR 56.7 million). The net amount of invoiced services in the end customer business (B2C) rose by an even higher 12.4 percent to EUR 55.3 million (9M 2023: EUR 49.2 million), with the share of this attributable to annual recurring payments increasing by 6.5 percent to EUR 16.6 million (9M 2023: EUR 15.6 million). “Our churn rate remains well below 1 percent,” Thomas Pfaadt, CFO of Vita 34 AG adds. “This pays in on our solid multi-year contract base, which keeps generating high levels of cash flows for the years to come.”

With an overall positive business performance, the situation on the individual European markets in the new customer business remains mixed. Important markets such as Germany and Portugal continued to show weakness in the third quarter whilst Switzerland, Spain, Romania and – once again – the GCC region developed positively. “In general, the overall low market penetration of cell banking in the markets we operate in offers a huge opportunity for us. Germany, the UK and Turkey are still showing penetration rates far below 1 percent compared to Romania, Portugal and Hungary with more than 5 percent.” explains Jakub Baran, CEO of Vita 34 AG. “Overall, we are optimistic about the fourth quarter and beyond and hope to return to past performance in the near future.”

EBITDA increased significantly by 77.5 percent year-on-year to EUR 6.4 million (9M 2023: EUR 3.6 million). The EBITDA was positively impacted by a special effect of EUR 1.4 million from new agreements with the US licensor of the CAR-T technology. Despite growing investments in marketing and sales in the third quarter as a result of the marketing offensive launched, the Company was able to keep a firm grip on costs and realize potential savings. Important steps were also taken in the third quarter as part of the Group-wide integration efforts. Further core processes in the Company were digitalized.

The key figures for business development are as follows:

	IFRS, in EUR `000	Q3	Q3	Q3	9M	9M	9M
		2024	2023	∆	2024	2023	∆
	Revenues	22,232	20,412	8.9%	60,262	56,682	6.3%
	Gross profit	8,586	8,939	-4.0%	22,679	21,360	6.2%
	EBITDA	3,636	2,039	78.3%	6,371	3,590	77.5%
	EBITDA margin	16.4%	10.0%	+6.4 PP	10.6%	6.3%	+4.3 PP
	EBIT	1,453	-89	>100%	-282	-2,823	90.0%
	Result for the period	1,112	-1,606	>100%	-1,255	-5,830	78.5%
	Earnings per share [EUR]	0.06	-0.10	>100%	-0.06	-0.35	82.9%
	Operating cash flow	—	—	—	7,789	4,834	61.1%
	Cash & cash equivalents (vs. 31 Dec. 2023)	—	—	—	17,626	17,416	1.2%

Cash flow from operating activities continued to increase, and rose by 61.1 percent to EUR 7.8 million (9M 2023: EUR 4.8 million). As in the previous quarters, high demand for prolongations of expiring contracts contributed to this. Cash and cash equivalents also continued to develop positively at EUR 17.6 million, underpin the Group’s sustained solid financial position.

Furthermore the Company continues to see a growing demand on the customer side for higher-value product bundles. Based on the positive experience from the Swiss and GCC markets, the Company decided to roll-out placenta tissue banking in Poland and Romania. Given the high demand currently seen at market launch, it is planned to roll out placenta banking across all of Europe. In parallel, several initiatives regarding partnerships in cell therapies with clinical centers and hospitals have been started. Vita 34 is recognized as a reliable partner in the industry providing services of collection, testing, processing and storage of perinatal tissue.

The Management Board maintains its full year guidance of revenues between EUR 81 million and EUR 88 million and EBITDA of EUR 6.5 million to EUR 8.0 million. The guidance is based on a constant exchange rate of the euro against the Polish zloty and other currencies (HUF, RON, TRY, GBP) compared to 29 April 2024.

The Management Board of Vita 34 AG will be available to institutional investors, analysts and representatives of the press today at 11:00 a.m. in a video conference to provide additional information on business development. Registration for this is by e-mail via the Investor Relations department (ir@vita34.de).

Contact:
Vita 34 AG
Investor Relations
Phone: +49 (0341) 48792 – 40
Email: ir@vita34.de

Company Profile

Vita 34 was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. The donor’s own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at Vita 34. Furthermore, the Company is active in the areas of Cell & Gene therapies and CDMO.

(Hong Kong, 21 November 2024) – Modern Dental Group Limited (the “Modern Dental Group” or the “Group”, Stock Code: 03600.HK), a leading global dental prosthetics provider, is pleased to announce the acquisition (“the acquisition”) of 74% shares in Hexa Ceram Dental Laboratory (“Hexa Ceram”) – the largest dental laboratory in terms of market share in Thailand. The acquisition builds on the Group’s strategy in expanding distribution networks and penetration into new geographic markets and utilizing Hexa Ceram as a production base for Southeast Asia, which helps reinforce the Group’s global leadership in the ever-evolving dental industry.

 

Expansion of Market Reach in the Global Distribution Network

Hexa Ceram Dental Laboratory is the largest dental laboratory in Thailand, with a substantial market share of 28% during the year of 2022. It has been the pioneer in the industry for nearly 30 years and is dedicated to providing high-quality dental prosthetics to dentists, with a team of over 900 qualified dental technicians and the biggest sales team in 12 branches over Thailand. Hexa Ceram has demonstrated a solid performance which realized its net sales growth with a CAGR of 23% over the financial years 2020 to 2023; and the profitability with an EBITDA margin of 21% and a net profit margin of 18% in 2023. Upon the acquisition, the Group has significantly increased market share and strengthened its market position in Southeast Asian countries.

 

The Group will fully leverage Hexa Ceram’s strong market position and close connection with dental universities in Thailand to expand its local market reach. By utilizing the established skilled workforce in the laboratory, the Group will further enhance production flexibility, diversify the risk of concentration of production centers and enhance its overall production efficiency. By utilizing Hexa Ceram as a production base for the Southeast Asia market, the acquisition sets a significant milestone in the business journey of the Group, providing it with the resources and customer base necessary to enhance its product offerings and expand the market reach.

 

Unleashing the Full Potential to Develop in the Emerging Markets

Southeast Asia is a dynamic and rapidly evolving region with rising demand for dental services which is significantly influenced by increasing awareness of dental health, rising disposable income and expanding middle class in Southeast Asian countries. Thailand is well-established as a medical tourism hub and the robust healthcare infrastructure, provides unparalleled advantages and cultural diversity to serve as a convenient access point for neighboring countries.

 

The acquisition underscores Modern Dental Group’s commitment and determination to develop in the emerging markets and allows streamlined expansion of customer base and brand presence in Southeast Asia. The Group aims to unleash the full potential of its competitiveness to provide high-quality dental services at competitive prices. Upon the completion of the acquisition, the Group is positioned to enhance its coverage and penetration in the surrounding markets and provide high-quality and innovative dental solutions and services, given the established and growing presence in ASEAN Economic Community including Laos, Cambodia and Myanmar by Hexa Ceram. The Group is poised to unlock substantial growth opportunities and deliver even greater value to its customers.

 

Strategic M&A Strengthened the Group’s Competitive Edge

Since 2011, the Group has tactically expanded its global sales and distribution network across Europe, North America and Asia Pacific through a series of strategic acquisitions. Currently, Modern Dental Group has established a global sales network covering more than 23 countries. The Group’s expansive global presence allows the Group to deliver cutting-edge innovation and solutions to dentists around the world. It is believed that the streamlined operations and integrated supply chain through the acquisition will lead to improved efficiencies in sales and distribution, empower the Group a wider customer demographic to better meet the global demand and enhance its resilience to uncertainty in the macro environment.

 

Future Prospect

The management of Modern Dental Group stated, “We are delighted to welcome the team from Hexa Ceram. The combined extensive experience and network from Hexa Ceram enables us to be a more competitive, growth-oriented dental solutions provider in the evolving industry. We are well-positioned to deliver greater value for dentists and partners, as well as providing compelling alternatives in the new era of technological innovation to meet customers’ needs that exceed their expectations.”

 

The acquisition is an important step in the Group’ global expansion strategy. It has not only strengthened its presence over core markets in Southeast Asia but also enhanced the stability of its global supply chain and distribution network. Going forward, customers will benefit from a more competitive portfolio of solutions supported by the Group’s multifaceted dental ecosystem. The Group will continue to integrate global resources and technology to offer superior dental products and services, reinforcing the leading position in the global market.

 

About Modern Dental Group

Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.

 

Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA in the United States, and Southern Cross Dental in Australia. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 23 countries and serve over 30,000 customers.

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
 

• Zentiva waives the condition of minimum acceptance
• Acceptance Period ends unchanged today, 21 November 2024 at 24:00 CET
• Around 60% of shares already tendered
• Management Board and Supervisory Board of APONTIS PHARMA recommend acceptance of the Offer
• Investment agreement provides for termination of inclusion (delisting) in the open market (Freiverkehr)

Monheim / Rhein, 21 November 2024. The Management Board of APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5, “APONTIS PHARMA”), a leading pharmaceutical company specializing in Single Pill combinations in the German market, has been informed by Zentiva AG (the “Bidder”) in the context of the public purchase offer that the Bidder waives the condition of minimum acceptance. The Acceptance Period for the purchase offer remains unchanged and continues to end today, 21 November 2024 at 24:00 CET. After expiry of the Acceptance Period, the amended Offer can no longer be accepted.

On 19 November 2024, Zentiva announced to waive the minimum acceptance condition in the voluntary public purchase offer (the “Offer”) to acquire all outstanding shares of APONTIS PHARMA. All contracts concluded prior to or simultaneously with the amendment by the acceptance of the Offer will be automatically adapted to the amended terms and conditions. APONTIS PHARMA shareholders who have already accepted the Offer are not required to take any further actions in order to receive the offer price in accordance with the terms and conditions of the amended Offer. The amendment to the offer document is available online in German at www.zentiva-offer.com along with a non-binding English translation of the amendments to the offer document.

As of 20 November 2024, 15:00 CET, according to the information of the Bidder, the sum of (i) APONTIS PHARMA shares for which the Offer has been accepted and (ii) APONTIS PHARMA shares acquired by the Bidder pursuant to the Share Purchase Agreement (as defined below) amounts to 5,015,989 APONTIS PHARMA shares. This corresponds to approx. 60.22% of the voting share capital of APONTIS PHARMA.

Zentiva and APONTIS PHARMA have agreed in the Investment Agreement that APONTIS PHARMA’s Management Board will, to the extent permitted by law and subject to its fiduciary duties, terminate the inclusion of the APONTIS PHARMA shares in the trading on the open market (Freiverkehr) immediately following the settlement of the Offer. A separate delisting offer will not be required.

In their previously published joint reasoned statement, the Management Board and the Supervisory Board of APONTIS PHARMA have recommended all APONTIS PHARMA shareholders to accept the Offer, and have confirmed that they will tender all shares held by them into the Offer. All members of the Management Board and the Supervisory Board holding APONTIS PHARMA shares have already tendered their shares. Paragon, the main shareholder of APONTIS PHARMA, has entered into a Share Purchase Agreement for its stake of approx. 37.5% of APONTIS PHARMA’s share capital at a cash consideration of EUR 9.00 per share (“Share Purchase Agreement”), emphasizing the attractiveness of the offer price.

The cash consideration of EUR 10.00 represents a premium of 52.9% over the closing price of the APONTIS PHARMA share on 15 October 2024, and a premium of 38.3% on the weighted average price of the APONTIS PHARMA share over the three months ending 15 October 2024. This is well above comparable transactions in Germany over the past three years, whose average premium is 31.4%.[1]

The other offer conditions set out in the offer document, including the regulatory clearances, remain unaffected by the amendment of the Offer. Merger control clearance for the transaction was already granted on 12 November 2024.

“Zentiva AG’s offer to acquire the outstanding shares of APONTIS PHARMA has already been accepted by a majority of shareholders. The current analyst studies also have a price target of EUR 10.00, which corresponds to a significant premium compared to the value prior to the announcement of the Offer. We can only recommend that our shareholders accept the Offer and refer to the deadline on 21 November. According to the investor agreement, the shares will eventually be delisted”, said Bruno Wohlschlegel, CEO of APONTIS PHARMA.

Important notice

The information in this publication does not constitute explanations or additions to the statements in the reasoned statement. Only the joint reasoned statement of the Management Board and Supervisory Board of APONTIS PHARMA is binding.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, promoting, and distributing a broad portfolio of Single Pill combinations and other pharmaceutical products since 2013, with a special focus on cardiovascular diseases such as hypertension, hyperlipidemia, and secondary prevention. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Rolf-Schwarz-Schütte Platz 1
40789 Monheim / Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330

Disclaimer – Legal notice

The information contained in this press release may include certain forward-looking statements that are based on current assumptions and forecasts made by the management of APONTIS PHARMA AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Such factors include those discussed in APONTIS PHARMA AG’s public reports. These reports are available on www.apontis-pharma.de. The Company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.

^[1] Source: S&P Global, German M&A Deal Premiums: deal premium 1 day before announcement 31.4% on average over the past 3 years; sample: 31 PTOs in Germany with a transaction value >USD30M.

Berlin and Würzburg, Germany, November 21, 2024 – Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by the French Ministry of Health and led by a renowned investigator team from the University Hospital in Nantes, represents a significant step toward expanding targeted radiotherapy options for hematologic malignancies.

The investor-initiated study, named PENTILULA (ClinicalTrials.gov ID: NCT06356922) is a multicenter, open-label trial in which up to 21 patients with relapsed/refractory AML or ALL will be enrolled over a period of 24 months, with a total study duration of 36 months. The primary objective is to determine the maximal tolerated dose (MTD) of Lu177-PentixaTher, and to examine key efficacy parameters such as overall response rate (ORR) and complete remission (CR) after infusion of the novel radiotherapeutic agent.

Following a peer-reviewed publication in January 2023 in the prestigious Journal of Nuclear Medicine highlighting promising clinical results in the treatment of patients suffering from T-cell lymphoma, further evidence continues to be built up about the potential of Pentixapharm’s lead candidate, PentixaTher, for the treatment of haemato-oncological diseases.

The study is significant for Pentixapharm insofar as the incidence of ALL and AML, and hence the medical need, is much higher than that for T-Cell lymphoma. The PENTILULA trial is the first trial that combines PentixaTher with Lutetium-177, a radioisotope widely and successfully used for the treatment of castration resistant prostate cancer or neuroendocrine tumors.

Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive and life-threatening blood cancers that affect thousands of people worldwide each year. AML is the most common type of acute leukemia in adults, with an incidence of approximately 20,000 new cases per year and low five-year survival rate of 31.9% in the United States [1]. ALL is the most common type of cancer in children, with a high incidence in adults as well. Current treatment options often involve intensive chemotherapy and stem cell transplantation, which can have severe side effects. Effective radiotherapies in other indications are currently reimbursed with more than 100,000 USD per patient.

“Although treatments for acute leukemia have advanced, many patients continue to have limited options and face poor outcomes. We believe PentixaTher holds significant potential to address these unmet needs, offering a valuable radiopharmaceutical theranostic approach tailored to the individual patients with hematologic malignancies.” explains Dr. Dirk Pleimes, Group CEO and CMO at Pentixapharm. “We are delighted that leading experts such as Professor Françoise Kraeber-Bodéré of the Nuclear Medicine Department and Professor Patrice Chevallier of the Hematology Department in Nantes have decided to initiate this study to evaluate this novel radiotherapeutic treatment option. We are committed to providing our full support, leveraging our therapeutic knowledge with PentixaTher and facilitating access to the compound to drive this important research forward.”

Professor Françoise Kraeber-Bodéré is the Head of the department of Nuclear Medicine at the University Hospital in Nantes, France, and an expert of the Oncology committee of the French Society of Nuclear Medicine (SFMN) as well as of the Oncology and Therapy committee of the European Association of Nuclear Medicine. She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist in Hematology and member of the executive committee and scientific council of HéMA, an umbrella organization for hemato-oncological research in Western France.

About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Its Pipeline includes PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68 based companion diagnostic for blood cancers and cardiovascular diseases.

PentixaTher is an innovative radiotherapeutic that specifically targets the chemokine-4 receptor (CXCR4). Background material about its potential for the treatment of haematooncological diseases can be found at: https://edoc.mdc-berlin.de/id/eprint/24012/1/24012oa.pdf

About Nantes University Hospital

Nantes University Hospital (CHU de Nantes) is one of France’s leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting thousands of clinical trials and contributing to significant advancements in healthcare.
 

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
ir@pentixapharm.com
Tel. +49 30 94893232
www.pentixapharm.com

 

[1] https://seer.cancer.gov/statfacts/html/amyl.html

MPH Health Care AG: Preliminary IFRS result Q3/2024

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Berlin, 21. November 2024 – MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS consolidated result for the first nine months of the 2024 financial year. Accordingly, equity increased by EUR 49.3 million to EUR 300.3 million as of 30 September 2024 (previous year 31 December 2023: EUR 251.0 million). The net asset value (NAV) per share increased by 39% year-over-year from EUR 50.38 (30/09/2023) to EUR 70.14 as of 30/09/2024.

In the first nine months of 2024, EBIT amounted to EUR 55.6 million (Jan – Sep 2023: EUR -5.6 million). At the same time, the IFRS result for the period increased significantly to EUR 54.5 million (previous year: EUR -5.7 million). The equity ratio improved slightly to 94.85% as of 30 September 2024 (31 December 2023: 94.22%) and remains at a very high level.

MPH AG is an investment company whose investments are recognised as financial assets under the balance sheet item ‘Financial assets’ and are measured at fair value through profit or loss as at the balance sheet date. The net profit for the period is mainly the result of the fair value measurement of the listed investments held as at the balance sheet date, which result from the higher market prices of the investments compared to the previous year’s reporting date of 31 December 2023. 

The investments M1 Kliniken AG and CR Energy AG, which are listed on the Frankfurt Stock Exchange, were operationally successful in the 2023 financial year and in the first nine months of 2024.

M1 Kliniken AG was able to further expand its market position in the field of beauty medicine in the current year 2024 and opened five new specialist medical centres in Germany and abroad. According to the preliminary IFRS figures, the M1 Group’s consolidated sales increased by around 9% to EUR 257.2 million. The operating result (EBIT) increased by 71% and rose to EUR 22.1 million (previous year: EUR 12.9 million). Net income (after minority interests) as of 30 September 2020 rose to EUR 14.3 million, an increase of 247% compared to the same period of the previous year (EUR 4.1 million).

The share price of M1 Kliniken AG rose by 53% from EUR 11.20 on 31 December 2023 to EUR 17.10 on 30 September 2024.

Our second direct listed investment CR Energy AG does not publish quarterly figures as of 30 September 2024. As of 30 June 2024, CR Energy’s operating income was around EUR 9.4 million, taking into account the transfers from the investments. CR Energy is increasingly involved in the renewable energy supply and sustainable living sectors, whose markets are worth billions. In the near future, the investment CR Opportunities GmbH is also expecting approval for the issue of a European Long Term Investment Fund (ELTIF). A Reserved Alternative Investment Fund (RAIF) was already launched in the first half of 2024, which will eventually be supplemented by the ELTIF, which is intended to address institutional investors in the long term.

The share capital of CR Energy AG increased by EUR 17,640,654 from EUR 5,880,218 to EUR 23,520,872 following the entry of the Annual General Meeting resolution in the commercial register on 5 July 2024. The company’s shareholders are entitled to the bonus shares based on their shareholdings at a ratio of 1:3, meaning that shareholders receive an additional three bonus shares for every one existing share.

The CR Energy AG share price fell from (converted) EUR 7.23 on 31 December 2023 to EUR 6.04 on 30 September 2024.

‘Despite the ongoing conflict situations in Ukraine and the Middle East, we are confident about the development of the rest of 2024. The M1-Group will continue to drive profitable sales growth at its domestic and foreign locations and confirms its medium-term targets. Accordingly, the M1-Group will continue on its dynamic growth path – both in terms of sales and profits as well as global expansion – and plans to generate annual sales of EUR 200 to 300 million in the Beauty segment with an EBIT margin of at least 20% by the end of 2029. CR Energy AG is also very well positioned with its vertically integrated investment portfolio in the areas of ‘sustainable energy supply concepts’ and ‘quality and cost-optimised living space’. MPH AG can also systematically benefit from the positive developments of the investments in the coming years,’ says Patrick Brenske, CEO of MPH.
 

About MPH Health Care AG:

MPH Health Care AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. However, MPH also utilises the potential offered by high-growth and profitable sectors outside the healthcare market.

Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.

 

New Sales Record: Cantourage Group SE Reports EUR 5.5 Million in Revenue for October 2024, Reaffirming Full-Year Growth Targets
 

Berlin, November 20, 2024 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe’s leading listed cannabis company, continues its robust growth trajectory, achieving a historic monthly revenue of EUR 5.5 million in October 2024. This milestone underscores the rising demand for Cantourage’s products and solidifies its position as a leader in the European medical cannabis market.

With the record October sales and another positive operating result, Cantourage is on track to meet its annual targets of at least EUR 40 million in sales and EUR 2.0 million EBITDA for 2024. This achievement reaffirms the company’s commitment to sustainable growth.

“October was yet another record-breaking month, further proving that our strategy and business model rest on a strong foundation,” said Philip Schetter, CEO of Cantourage Group SE. “The continuous expansion of our product portfolio and the flexibility of our sourcing model empower us to thrive in Europe’s dynamically growing market environment.”

For further details on recent business developments and analysts’ growth projections for the coming years, please visit the “Investors” section of our website at www.cantourage.com/investors.

 

About Cantourage

Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH.”

Further information: www.cantourage.com

 

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

 

Press contact at Cantourage:

Frederick Steudemann
Tel. +49 (0)30 4701 350 – 50
steudemann@cantourage.com